Medical research

A novel radioisotope therapy for children with neuroblastoma

Researchers from Kanazawa University retrospectively analyzed children with refractory or relapsed high-risk neuroblastoma who were treated with high-dose 131I-metaiodobenzylguanidine at Kanazawa University Hospital. They ...

Oncology & Cancer

Chimeras offer a new way to study childhood cancers in mice

In a new paper published March 5 in the journal Cell Stem Cell, researchers in Whitehead Institute Member Rudolph Jaenisch's lab introduce a new way to model human neuroblastoma tumors in mice using chimeras—in this case, ...

Oncology & Cancer

Prozac fights deadly childhood brain cancer

The anti-depressant drug Prozac could be used to tackle one of the deadliest childhood tumours and possibly other types of cancer, scientists said.

Oncology & Cancer

Research sheds important light on the metastasis of neuroblastoma

Neuroblastoma can grow and spread in the body very aggressively, making it very difficult to treat. New research has shed important light on the factors at play in the metastasis of neuroblastoma, which could potentially ...

Oncology & Cancer

Neuroblastoma: Improved treatment prospects in future

Neuroblastoma is a rare form of malignant tumor, primarily affecting children under the age of six. A research team led by molecular pathologist Lukas Kenner from MedUni Vienna's Department of Pathology has now discovered, ...

page 1 from 13

Neuroblastoma

Neuroblastoma is the most common extracranial solid cancer in childhood and the most common cancer in infancy, with an annual incidence of about 650 new cases per year in the US. Close to 50 percent of neuroblastoma cases occur in children younger than two years old. It is a neuroendocrine tumor, arising from any neural crest element of the sympathetic nervous system or SNS. It most frequently originates in one of the adrenal glands, but can also develop in nerve tissues in the neck, chest, abdomen, or pelvis.

Neuroblastoma is one of the few human malignancies known to demonstrate spontaneous regression from an undifferentiated state to a completely benign cellular appearance.

A disease exhibiting extreme heterogeneity, neuroblastoma is stratified into three risk categories: low, intermediate, and high risk. Low-risk disease is most common in infants and highly curable with observation only or surgery, whereas high-risk disease is difficult to cure even with the most intensive multi-modal therapies available.

Note: Esthesioneuroblastoma, also known as olfactory neuroblastoma, is believed to arise from the olfactory epithelium and its classification remains controversial. However, since it is not a sympathetic nervous system malignancy it is a distinct clinical entity and is not to be confused with neuroblastoma.

This text uses material from Wikipedia, licensed under CC BY-SA